News

AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly
A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...
Medscape2d
New PCSK9 Gets Cholesterol to Target if Statins Can't
An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...
Managed Healthcare Executive2d
Verve’s One-Time Gene Editor Cuts LDL by Nearly 70% in Early Trial
A phase 1b showed promising results in lowering LDL in patients with heterozygous familial hypercholesterolemia and/or ...
BioSpace4d
Verve’s Base Editor “Numerically Beats” Other Cholesterol-Lowering Drugs
In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...
NewsNation6d
High cholesterol from keto diet not linked to heart disease: Study
100 people who followed a low-carb keto diet were analyzed and high cholesterol was found to not be a marker for increased ...
'Landmark' moment as new pill that fights breast cancer approved
A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is ...
NewsNation on MSN8d
AstraZeneca’s pill cuts cholesterol, offers convenient treatment
AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...
Healio10d
Daily oral PCSK9 inhibitor cut LDL cholesterol by 50% over 12 weeks
In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...
MyChesCo on MSN11d
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial
New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers ...
STAT14d
Cuts, ousters and drama at the FDA
On The Readout LOUD podcast, STAT reporters talk about new FDA commissioner Marty Makary's first week amid a swirl of layoffs ...
Pharmabiz16d
AstraZeneca’s AZD0780, a novel oral PCSK9 inhibitor, demonstrates significant LDL cholesterol reduction in PURSUIT phase IIb trial
Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...